View Financial HealthRevium Rx 配当と自社株買い配当金 基準チェック /06Revium Rx配当金を支払った記録がありません。主要情報n/a配当利回り-0.003%バイバック利回り総株主利回り-0.003%将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesお知らせ • Oct 22Revium Recovery Inc. Advances Toward Phase 1 Clinical Development of Nano-Mupirocin to Combat Antibiotic-Resistant InfectionsRevium Rx announced significant progress in its regulatory and manufacturing programs supporting the planned Phase 1 clinical trial of its lead product candidate, Nano-Mupirocin - a novel systemic formulation of the well-known and highly potent antibiotic mupirocin. Last month, the company submitted its clinical trial application to the Israeli Ministry of Health, marking a critical milestone toward the initiation of first-in-human studies in early 2026. Concurrently, Revium Rx, in collaboration with WuXi AppTec, one of the world's leading global CDMOs, continues to advance the scale-up and production of its GMP clinical batch, with final release expected by the end of 2025. Addressing the Urgent Threat of Antimicrobial Resistance (AMR) In 2021, Methicillin-Resistant Staphylococcus Aureus (MRSA) was estimated to have caused approximately 130,000 deaths directly attributable to antimicrobial resistance (AMR) -- a sharp rise from 57,200 in 1990. According to the Global Research on Antimicrobial Resistance (GRAM) Project published in The Lancet in 2022, MRSA was responsible for over 100,000 AMR-attributable deaths in 2019, making it one of the deadliest pathogens that year. The global AMR therapeutics market was valued at USD 8.7 billion in 2023 and is projected to exceed USD 12.5 billion by 2030, growing at a CAGR of 5.3 %, according to Grand View Research, 2024. Within this rapidly expanding global market, Nano-Mupiroci targets several high-value infectious disease indications, including Methicillin-ResistantStaphylococcus aureus (MRSA), Vancomycin-Resistant Enterococci (VRE), and Ceftriaxone-Resistant Gonorrhea (CR-Gonorrhea). If Nano-Mupirocin demonstrates favorable results in clinical trials, of which no assurance can be provided, the Company will seek to capture a meaningful share within this rapidly expanding market, reflecting both the urgent clinical need and the significant commercial potential of novel antibiotics effective against resistant pathogens.お知らせ • Feb 14Revium Recovery Inc. has filed an IPO in the amount of $5 million.Revium Recovery Inc. has filed an IPO in the amount of $5 million. Security Name: Units Security Type: Equity/Derivative Unit Securities Offered: 1,562,500 Price\Range: $3.2 Discount Per Security: $0お知らせ • Feb 06Revium Recovery Inc. (OTCPK:RVRC) completed the acquisition of LipoVac, Ltd.Revium Recovery Inc. (OTCPK:RVRC) entered into a letter of intent to acquire LipoVac, Ltd. on December 20, 2022. Revium Recovery will issue shares in exchange for all of LipoVac’s outstanding capital stock. The transaction is subject to satisfactory due diligence by the parties and the entry into a definitive merger agreement. The transaction is also subject to Revium completing a private placement of its securities with net proceeds to Revium of at least $7 million. Revium Recovery Inc. (OTCPK:RVRC) completed the acquisition of LipoVac, Ltd. on February 4, 2025.お知らせ • Dec 22Revium Recovery Inc. (OTCPK:RVRC) entered into a letter of intent to acquire LipoVac, Ltd.Revium Recovery Inc. (OTCPK:RVRC) entered into a letter of intent to acquire LipoVac, Ltd. on December 20, 2022. Revium Recovery will issue shares in exchange for all of LipoVac’s outstanding capital stock. The transaction is subject to satisfactory due diligence by the parties and the entry into a definitive merger agreement. The transaction is also subject to Revium completing a private placement of its securities with net proceeds to Revium of at least $7 million.決済の安定と成長配当データの取得安定した配当: RVRCの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: RVRCの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場Revium Rx 配当利回り対市場RVRC 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (RVRC)n/a市場下位25% (US)1.4%市場トップ25% (US)4.3%業界平均 (Pharmaceuticals)2.1%アナリスト予想 (RVRC) (最長3年)n/a注目すべき配当: RVRCは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: RVRCは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: RVRCの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: RVRCが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YUS 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 02:24終値2026/03/30 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Revium Rx. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Oct 22Revium Recovery Inc. Advances Toward Phase 1 Clinical Development of Nano-Mupirocin to Combat Antibiotic-Resistant InfectionsRevium Rx announced significant progress in its regulatory and manufacturing programs supporting the planned Phase 1 clinical trial of its lead product candidate, Nano-Mupirocin - a novel systemic formulation of the well-known and highly potent antibiotic mupirocin. Last month, the company submitted its clinical trial application to the Israeli Ministry of Health, marking a critical milestone toward the initiation of first-in-human studies in early 2026. Concurrently, Revium Rx, in collaboration with WuXi AppTec, one of the world's leading global CDMOs, continues to advance the scale-up and production of its GMP clinical batch, with final release expected by the end of 2025. Addressing the Urgent Threat of Antimicrobial Resistance (AMR) In 2021, Methicillin-Resistant Staphylococcus Aureus (MRSA) was estimated to have caused approximately 130,000 deaths directly attributable to antimicrobial resistance (AMR) -- a sharp rise from 57,200 in 1990. According to the Global Research on Antimicrobial Resistance (GRAM) Project published in The Lancet in 2022, MRSA was responsible for over 100,000 AMR-attributable deaths in 2019, making it one of the deadliest pathogens that year. The global AMR therapeutics market was valued at USD 8.7 billion in 2023 and is projected to exceed USD 12.5 billion by 2030, growing at a CAGR of 5.3 %, according to Grand View Research, 2024. Within this rapidly expanding global market, Nano-Mupiroci targets several high-value infectious disease indications, including Methicillin-ResistantStaphylococcus aureus (MRSA), Vancomycin-Resistant Enterococci (VRE), and Ceftriaxone-Resistant Gonorrhea (CR-Gonorrhea). If Nano-Mupirocin demonstrates favorable results in clinical trials, of which no assurance can be provided, the Company will seek to capture a meaningful share within this rapidly expanding market, reflecting both the urgent clinical need and the significant commercial potential of novel antibiotics effective against resistant pathogens.
お知らせ • Feb 14Revium Recovery Inc. has filed an IPO in the amount of $5 million.Revium Recovery Inc. has filed an IPO in the amount of $5 million. Security Name: Units Security Type: Equity/Derivative Unit Securities Offered: 1,562,500 Price\Range: $3.2 Discount Per Security: $0
お知らせ • Feb 06Revium Recovery Inc. (OTCPK:RVRC) completed the acquisition of LipoVac, Ltd.Revium Recovery Inc. (OTCPK:RVRC) entered into a letter of intent to acquire LipoVac, Ltd. on December 20, 2022. Revium Recovery will issue shares in exchange for all of LipoVac’s outstanding capital stock. The transaction is subject to satisfactory due diligence by the parties and the entry into a definitive merger agreement. The transaction is also subject to Revium completing a private placement of its securities with net proceeds to Revium of at least $7 million. Revium Recovery Inc. (OTCPK:RVRC) completed the acquisition of LipoVac, Ltd. on February 4, 2025.
お知らせ • Dec 22Revium Recovery Inc. (OTCPK:RVRC) entered into a letter of intent to acquire LipoVac, Ltd.Revium Recovery Inc. (OTCPK:RVRC) entered into a letter of intent to acquire LipoVac, Ltd. on December 20, 2022. Revium Recovery will issue shares in exchange for all of LipoVac’s outstanding capital stock. The transaction is subject to satisfactory due diligence by the parties and the entry into a definitive merger agreement. The transaction is also subject to Revium completing a private placement of its securities with net proceeds to Revium of at least $7 million.